Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The study record for the pembrolizumab-with-or-without-lenvatinib trial is now displayed, including detailed study information and posted results, where the page previously showed a forbidden error.
    Difference
    100%
    Check dated 2026-11-10T21:55:05.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site revision label in the footer changed from v3.7.2 to v3.8.0; the study record page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T22:02:12.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a website transition and related terminology update. The site revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T21:44:42.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T21:41:18.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the previous study record content with an access-denied screen. As a result, the core trial details and navigation are no longer visible, hindering user access to sponsor information, locations, eligibility criteria, and interventions.
    Difference
    19%
    Check dated 2026-09-22T22:39:05.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The revision label on the page was updated from v3.6.6 to v3.7.0. This indicates an updated edition of the study documents.
    Difference
    0.0%
    Check dated 2026-09-15T20:47:08.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.